非小细胞肺癌的新辅助靶向治疗及其对手术结局的影响。
Neoadjuvant Targeted Therapy in Non-Small Cell Lung Cancer and Its Impact on Surgical Outcomes.
作者信息
Sorin Mark, Huynh Caroline, Rokah Merav, Dubé Laurie-Rose, Rayes Roni, Ofiara Linda, Shieh Benjamin, Owen Scott, Fiset Pierre Olivier, Cammilleri-Broët Sophie, Najmeh Sara, Cools-Lartigue Jonathan, Ferri Lorenzo, Spicer Jonathan D
机构信息
Rosalind and Morris Goodman Cancer Research Centre, McGill University, Montréal, Quebec, Canada.
Department of Human Genetics, McGill University Health Centre, Montréal, Quebec, Canada.
出版信息
Ann Thorac Surg Short Rep. 2022 Nov 25;1(1):102-106. doi: 10.1016/j.atssr.2022.11.014. eCollection 2023 Mar.
BACKGROUND
The evidence for neoadjuvant targeted therapy in non-small cell lung cancer is limited, with 2 phase 3 trials currently recruiting and no approved indications.
METHODS
We describe our experience with the use of neoadjuvant targeted therapy for patients with operable non-small cell lung cancer.
RESULTS
Our focus is on surgical outcomes, which represent an underreported aspect of the patient trajectory. We argue that surgical outcomes are an essential feature of this strategy with significant potential benefits and risks.
CONCLUSIONS
Overall, the patient experience can be significantly affected by the use of neoadjuvant targeted therapy and its impact on surgical planning, strategy, and outcomes.
背景
非小细胞肺癌新辅助靶向治疗的证据有限，目前有2项3期试验正在招募患者，且尚无获批的适应证。
方法
我们描述了对可手术切除的非小细胞肺癌患者使用新辅助靶向治疗的经验。
结果
我们关注的是手术结果，这是患者病程中一个报道较少的方面。我们认为手术结果是该治疗策略的一个基本特征，具有显著的潜在益处和风险。
结论
总体而言，新辅助靶向治疗的使用及其对手术规划、策略和结果的影响会显著影响患者体验。
Zotero 插件